News

Biomarkers for progression and repair in MS: the key to developing treatments for progressive forms of MS

10 December 2013

Related News

26 June 2025

The Pharmaceutical Benefits Advisory Committee has recommended ublituximab (Briumvi®) be listed on the PBS for treating relapsing remitting MS….

24 June 2025

CEO Rohan Greenland responds to the latest NDIS pricing decision, warning it threatens access to essential therapies and places additional…
Read More
needle

Newsletter subscription

  • Enter your details

Biomarkers for progression and repair in MS: the key to developing treatments for progressive forms of MS